Compare ACH & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACH | NTRB |
|---|---|---|
| Founded | 1882 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 72.6M |
| IPO Year | 2001 | 2019 |
| Metric | ACH | NTRB |
|---|---|---|
| Price | $0.25 | $6.35 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.26 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 33.6K |
| Earning Date | 11-05-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,762,032,000.00 | $2,036,651.00 |
| Revenue This Year | N/A | $4,584.65 |
| Revenue Next Year | $2.97 | $89.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.19 | $2.80 |
| 52 Week High | $4.69 | $9.19 |
| Indicator | ACH | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 25.02 | 49.17 |
| Support Level | $0.19 | $5.68 |
| Resistance Level | $1.26 | $9.19 |
| Average True Range (ATR) | 0.04 | 0.44 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 28.44 | 52.17 |
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.